- Home
- SOTK vs BCAB Comparison
SOTK vs BCAB Comparison
Compare SOTK & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOTK | BCAB |
|---|---|---|
| Founded | 1975 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 71.6M |
| IPO Year | 1987 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOTK | BCAB |
|---|---|---|
| Price | $3.91 | $0.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 17.4K | ★ 2.1M |
| Earning Date | 01-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.63 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $20,607,030.00 | N/A |
| Revenue This Year | $2.67 | N/A |
| Revenue Next Year | $8.20 | N/A |
| P/E Ratio | $40.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $0.24 |
| 52 Week High | $6.05 | $1.72 |
Technical Indicators
Market Signals| Indicator | SOTK | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 51.42 |
| Support Level | $3.40 | $0.76 |
| Resistance Level | $3.93 | $1.00 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 33.63 | 26.70 |
Price Performance
Historical ComparisonAbout SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.